Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riviciclib in Relapsed/Refractory Multiple Myeloma
NCT00882063Phase 2Completed
- Sponsor
- Piramal Enterprises Limited
- Start
- Jan 2008
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of P276 in multiple myeloma (MM), sponsored by Piramal Enterprises Limited. Primary endpoint: Maximum Tolerated Dose at 18 months. Started Jan 2008; status: completed.
02
Drugs
P276
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00882063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00882063.